Supplementary Figures 1 - 3 from BMN 673, a Novel and Highly Potent PARP1/2 Inhibitor for the Treatment of Human Cancers with DNA Repair Deficiency

PDF file - 150K, Supplementary Figure 1: BMN 673 induces DNA damage at lower doses and with higher intensity than olaparib. Supplementary Figure 2: BMN 673 is active in vivo against xenograft models with PTEN deficiency. Supplementary Figure 3: Balb/c nude mice carrying sc MDA-MB-468 xenograft tumors were treated with BMN673 at 0.33 mg/kg, QD or BMN673 at 0.165 mg/kg, BID for 28 consecutive days (Days 15-42 post tumor implantation) and the animals were terminated at Day 64 post tumor implantation.